Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update

Cellectar Biosciences, Inc.

, an oncology-focused biotechnology company, today provides an update on its recently initiated Phospholipid Drug Conjugate (PDC) chemotherapeutic program, CLR CTX. PDCs are a new class of small-molecules that employ Cellectar's extensively validated phospholipid ether-based cancer targeting and delivery vehicle. The PDC platform possesses the ability to link diverse oncologic payloads for targeted delivery to a broad range of cancers. The objective of the CLR CTX program is to develop PDC chemotherapeutics through conjugation of our delivery vehicle and multiple non-targeted anti-cancer agents to improve therapeutic indices and expand potential indications through the targeted delivery of chemotherapeutic payloads. "The potential advantages of drug candidates developed using the PDC delivery platform over classic cytotoxic approaches are broad-band tumor targeting, including brain metastases, and prolonged tumor cell retention, both of which have been validated by human imaging. Further, PDC delivery technology has demonstrated the ability to target human glioma stem cells ex vivo, suggesting the potential to provide targeted delivery of therapeutic agents to cancer stem cells," said John S. Kuo, MD, PhD, FAANS, FACS, Associate Professor of Neurological Surgery and Human Oncology (Tenure) Director, Comprehensive Brain Tumor Program Chair, CNS Tumors Working Group, Carbone Cancer Center, Center for Stem Cell and Regenerative Medicine at the University of Wisconsin-Madison.